Supplemental FIG. 1

```
                    10         20         30         40         50         60         70         80         90        99
pNL4-3 PR    PQITLWQRPL VTIKIGGQLK EALLDTGADD TVLEEMNLPG RWKPKMIGGI GGFIKVRQYD QILIEICGHK AIGTVLVGPT PVNIIGRNLL TQIGCTLNF

HIV_RTV^WK6  .......... .......... .......... .......... .....X.... .......... .......... .......... .A........ ........
                                                          (M/L)
HIV_RTV^WK18 .........F .......... .......... .......... .....L.... ...V...... .......... .......... .A........ ........

HIV_APV^WK8  .......... .......... .......... .......... .....X.... .......... .......... .......... .......... ........
                                                          (M/L)
HIV_APV^WK14 .......... .......... .......... .......... .....L.... .......... .......... .......... .......... ........
HIV_APV^WK20 .........F .......... .......... .I........ .....L.... .......... .......... .......... .......... ........
HIV_APV^WK26 .........F .......... .......... .IF....... .....L.... ...M...... .......... V......... .......... ........

HIV_DRV^WK7  .......... .......... .......... .......... .......... .......... .......... .......... .......... ........
HIV_DRV^WK14 .......... .......... .......... .......... .......... .......... .......... .......... .I........ ........
HIV_DRV^WK42 .......... .......... .......... .......... .......... .......... .......... .......... .I........ ........

HIV_1388^WK20 .......... .......... .......... .......... .......... .......... .......... .......... .......... ........
HIV_1388^WK45 .......... .......... .......... .......... .......... .......... .......... .......... .......... ........

HIV_1398^I-WK10 .......... .......... .......... .......... .......... .......... .......... .......... .......... ........
HIV_1398^I-WK20 .......... .......... .......... .......... .......... .......... .......... .......... .......... ........
HIV_1398^I-WK26 .........F .......... .......... .......... .....X...V .......... .......... .......... .......... ........
HIV_1398^I-WK32 .........F .......... .......... .......... .....X...V .......... .......... .......... .......... ........
HIV_1398^I-WK38 .........F .......... .......... .......... .....X...V .......... .......... .......... .......... ........
                                                          (M/I)
HIV_1398^I-WK45 .........F .......... .......... .......... .....IV..V .......... .......... X......... ...X...... ........
                                                                                          (A/V)      (I/V)

HIV_1398^II-WK10 .......... .......... .......... .......... .......... .......... .......... .......... .......... ........
HIV_1398^II-WK16 .......... .......... .......... .......... .......... .......... .......... .......... .......... ........
HIV_1398^II-WK22 .........F .......... .......... .......... .......... .......... .......... .......... .......... ........
HIV_1398^II-WK28 .........F .......... .......X.. .......... .....X.... .......... .......... .......... .......... ........
HIV_1398^II-WK36 .........F .......... .......X.. .......... .....X.... .......... .......... .......... .......... ........
HIV_1398^II-WK42 .........F .......... .......X.. .......... .....X.... .......... .......... .......... .......... ........
HIV_1398^II-WK49 .........F .......... .......X.. ..X....... .....X.... .......... .......... .......... .......... ........
                                   (A/S)      (L/F)      (M/I)
```

Supplemental FIG. 1 Amino acid sequences of protease-encoding regions of HIV-1$_{NL4-3}$ variants selected in the presence of DRV, GRL-1388, or GRL-1398. The amino acid sequence of protease, deduced from the nucleotide sequence of the protease-encoding region of each proviral DNA isolated at each indicated time, is shown. The "WK" number indicated in each HIV-1 denotes the week period of selection. The amino acid sequence of wild-type HIV-1$_{NL4-3}$ protease is illustrated at the top as a reference.

Supplemental FIG. 2

```
                 10        20        30        40        50        60        70        80        90        99
pNL4-3 PR       PQITLWQRPL VTIKIGGQLK EALLDTGADD TVLEEMNLPG RWKPKMIGGI GGFIKVRQYD QILIEICGHK AIGTVLVGPT PVNIIGRNLL TQIGCTLNF
HIV_MIX-DRV^WK3 .........I ...R...... .......... ..I..I.... .....I.... ..L.R..... .VP....... V.S....... .A.......M ..L..X...
                                                                                                                   (T/A)
HIV_MIX-DRV^WK6 .........V .E...A..IR .......... ..F.DIS... .....I...V ..LVR.K..E .VP....... V......... .A.......M .........
HIV_MIX-DRV^WK19 ........V .E...A..IR .......... .IFKDIS... .....I...V ..LVR.K..E .VP....... V.S....... .A.......M .........
HIV_MIX-DRV^WK21 ........V .E...A..IR .......... .IFKDIS... .....I...V ..LVR.K..E .VP....... V.S....... .A.......M ........


HIV_MIX-1388^WK3  .......I ....V....R ...I...... .....I.... .....L.... ...V...... .VP......Q ..S....... .A.......M. .........
HIV_MIX-1388^WK6  .......V .E...A..IR .......... ..F.DIS... .....I...V ..XVX.X..X .VP......X X......... .A......XX .........
                                                                            (F/L)(K/R)(R/K)(D/E)   (K/Q)(A/V)        (L/M)(L/M)
HIV_MIX-1388^WK12 .......V .E...A..IR .......... ..F.DIS... .....I...V ..LVR.K..E .VP....... V......... .A.......M .........
HIV_MIX-1388^WK17 .......V .E...A..IR .......... .XF.DIS... .....I...V ..LVR.K..E .VP....... V......... .A.......M .........
                                                   (V/I)


HIV_MIX-1398^WK3  .......I ...R...... .......... ..I..I.... .....I.... ..L.R..... .VP....... V.S....... .A.......M ..L.....
HIV_MIX-1398^WK6  .......I ...R...... .......... ..I..I.... .....I.... ..L.R..... .VP....... V.S....... .A.......M ..L.....
HIV_MIX-1398^WK12 .......I ...X...... .......... ..I..I.... .....I.... ..L.X.X... .VP....... V.S....... .A.......M ..L.....
                             (K/R)                                        (K/R)(R/K)
HIV_MIX-1398^WK18 .......I ....V..... .......... ..I..I.... .....I.... ..L.R..... .VP....... V.S....... .X.......M ..L.....
                                                                                                        (V/A)
HIV_MIX-1398^WK24 .......I ....V..... .......X.. ..I..I.... .....I...X ..L.R..... .VP....... V.S....... .X.......M ..L.....
                             (A/S)                          (I/V)                                       (V/A)
HIV_MIX-1398^WK29 .......I ....V..... .......X.. ..I..I.... .....I...X ..L.R..... .VP....... V.S....... .........M ..L.....
                             (A/S)                          (I/V)
```

Supplemental FIG. 2. Amino acid sequences of protease-encoding regions of $_{CL}$HIV-1$_{MIX}$ variants selected in the presence of DRV, GRL-1388, or GRL-1398.
The amino acid sequence of protease, deduced from the nucleotide sequence of the protease-encoding region of each proviral DNA isolated at each indicated time, is shown. The "WK" number indicated in each HIV-1 denotes the week period of selection. The top line shows the protease sequence of the wild-type pNL4-3 clone.